Based on the potential synergy observed between ilixadencel and drugs that inhibit immunosuppression (sunitinib and gemcitabine), including unpublished preclinical data indicating that ilixadencel and anti-PD-1 treatment have a synergistic anti-tumor effect in the CT-26 mouse tumor model, a new combination study is planned: this is a randomized, open-label, multicenter, phase Ib/II trial evaluating the safety and efficacy of intratumorally-administered ilixadencel in combination with checkpoint inhibitor (CPI) in advanced cancer subjects who are candidates for CPI therapy. This evidence concerns the gene PDCD1 and neoplasm.